Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients
- PMID: 18186813
- DOI: 10.1111/j.1398-9995.2007.01569.x
Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients
Abstract
Background: Excessive mast cell mediator release may lead to anaphylaxis in patients with mastocytosis. However, the incidence, clinical features and trigger factors have not yet been analyzed.
Methods: To identify risk factors for anaphylaxis in mastocytosis, we determined cumulative incidence, severity, clinical characteristics, and trigger factors for anaphylaxis in 120 consecutive patients (53 male; 67 female, median age and range 24 years, 1 month to 73 years), and correlated these with disease severity of mastocytosis, skin involvement, basal total serum tryptase, and diaminooxidase concentrations.
Results: The cumulative incidence of anaphylaxis in patients with mastocytosis was higher in adults (49%; P < 0.01) compared with that in children (9%). Only children with extensive skin involvement had experienced anaphylaxis. In adults, anaphylaxis was correlated to the absence of urticaria pigmentosa lesions (P < 0.03). Reactions occurred more frequently in adults with systemic (56%) when compared with cutaneous mastocytosis (13%; P < 0.02). In adults, 48% of reactions were severe, and 38% resulted in unconsciousness. Major perceived trigger factors for adults were hymenoptera stings (19%), foods (16%), and medication (9%); however, in 26% of reactions, only a combination of different triggers preceded anaphylaxis. Trigger factors remained unidentified in 67% of reactions in children compared with 13% in adults. Patients with anaphylaxis had higher basal tryptase values (60.2 +/- 55 ng/ml, P < 0.0001) in comparison with those without (21.2 +/- 33 ng/ml), but not diaminooxidase levels.
Conclusion: Adult patients and children with extensive skin disease with mastocytosis have an increased risk to develop severe anaphylaxis; thus, an emergency set of medication including epinephrine is recommended.
Comment in
-
Mastocytosis is not related to allergic diseases.Allergy. 2008 Sep;63(9):1248. doi: 10.1111/j.1398-9995.2008.01806.x. Allergy. 2008. PMID: 18699942 No abstract available.
Similar articles
-
Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase.Clin Exp Allergy. 2009 May;39(5):717-25. doi: 10.1111/j.1365-2222.2009.03210.x. Epub 2009 Mar 10. Clin Exp Allergy. 2009. PMID: 19302252
-
Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels.J Allergy Clin Immunol. 2009 Mar;123(3):680-6. doi: 10.1016/j.jaci.2008.11.018. Epub 2009 Jan 9. J Allergy Clin Immunol. 2009. PMID: 19135713
-
Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult cutaneous mastocytosis.Clin Exp Dermatol. 2009 Jun;34(4):462-8. doi: 10.1111/j.1365-2230.2008.03005.x. Clin Exp Dermatol. 2009. PMID: 19077102
-
[Mastocytosis and anaesthesia].Ann Fr Anesth Reanim. 2009 Jan;28(1):61-73. doi: 10.1016/j.annfar.2008.09.022. Epub 2008 Dec 18. Ann Fr Anesth Reanim. 2009. PMID: 19097849 Review. French.
-
Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis?Curr Allergy Asthma Rep. 2015 May;15(5):22. doi: 10.1007/s11882-015-0525-1. Curr Allergy Asthma Rep. 2015. PMID: 26139333 Review.
Cited by
-
Alpha-Tryptase as a Risk-Modifying Factor for Mast Cell-Mediated Reactions.Curr Allergy Asthma Rep. 2024 Mar 9. doi: 10.1007/s11882-024-01136-y. Online ahead of print. Curr Allergy Asthma Rep. 2024. PMID: 38460022 Review.
-
Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy.Vaccines (Basel). 2024 Feb 16;12(2):202. doi: 10.3390/vaccines12020202. Vaccines (Basel). 2024. PMID: 38400185 Free PMC article.
-
Reversible Elevation of Tryptase Over the Individual's Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS?Curr Allergy Asthma Rep. 2024 Feb 3. doi: 10.1007/s11882-024-01124-2. Online ahead of print. Curr Allergy Asthma Rep. 2024. PMID: 38308674 Review.
-
Predictors of Clonality and Underlying Mastocytosis in Mast Cell Activation Syndromes.Curr Allergy Asthma Rep. 2024 Feb;24(2):25-32. doi: 10.1007/s11882-023-01122-w. Epub 2024 Jan 25. Curr Allergy Asthma Rep. 2024. PMID: 38270805 Review.
-
Challenges in Drug and Hymenoptera Venom Hypersensitivity Diagnosis and Management in Mastocytosis.Diagnostics (Basel). 2024 Jan 5;14(2):123. doi: 10.3390/diagnostics14020123. Diagnostics (Basel). 2024. PMID: 38247999 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
